Published in Hepatology on January 01, 1998
The Physiology of Fatigue in Patients With Chronic Liver Disease | NCT01867385
Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut (1999) 2.98
Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart (2002) 2.91
HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health (2009) 1.62
Quality of life measurement in gastrointestinal and liver disorders. Gut (2000) 1.44
Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol (2006) 1.38
Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network. Hepatology (2009) 1.26
Fatigue is associated with high circulating leptin levels in chronic hepatitis C. Gut (2002) 1.21
Living with hepatitis C: qualitative interviews with hepatitis C-infected veterans. J Gen Intern Med (2008) 1.21
Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci (2007) 1.17
Health-related quality of life of Southern Chinese with chronic hepatitis B infection. Health Qual Life Outcomes (2009) 1.16
Generic and disease-specific health related quality of life in non-cirrhotic, cirrhotic and transplanted liver patients: a cross-sectional study. BMC Gastroenterol (2003) 1.13
Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. Gut (2006) 1.11
Effects of a self-care program on quality of life of cirrhotic patients referring to Tehran Hepatitis Center. Health Qual Life Outcomes (2005) 1.10
Psychometrics of the chronic liver disease questionnaire for Southern Chinese patients with chronic hepatitis B virus infection. World J Gastroenterol (2009) 1.09
Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy. Clin Pract Epidemiol Ment Health (2007) 1.08
Health-related quality of life and impact of antiviral treatment in Chinese patients with chronic hepatitis C in Taiwan. World J Gastroenterol (2005) 1.07
Chronic hepatitis C virus infection: does it really impact health-related quality of life? A study in rural Egypt. Hepatology (2004) 1.04
Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes. J Pediatr Gastroenterol Nutr (2009) 1.01
Health profile preferences of hepatitis C patients. Dig Dis Sci (2000) 1.00
Effect of ondansetron, a 5-HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomised, double blind, placebo controlled study. Gut (2005) 0.96
Neuropsychological alterations in hepatitis C infection: the role of inflammation. World J Gastroenterol (2011) 0.96
Impairments in fine-motor coordination and speed of information processing predict declines in everyday functioning in hepatitis C infection. J Clin Exp Neuropsychol (2008) 0.96
Factors influencing quality of life of people living with HIV in Estonia: a cross-sectional survey. J Int AIDS Soc (2009) 0.95
Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study. J Hepatol (2012) 0.95
Assessment of fatigue in patients with chronic hepatitis C using the Fatigue Impact Scale. Dig Dis Sci (2002) 0.94
Neuropsychiatric and psychosocial issues of patients with hepatitis C infection: a selective literature review. Hepat Mon (2013) 0.92
Fatigue in liver disease: pathophysiology and clinical management. Can J Gastroenterol (2006) 0.92
The burden of hepatitis C in Europe from the patients' perspective: a survey in 5 countries. BMC Gastroenterol (2013) 0.91
Management of opioid addiction in primary care: a pragmatic approach prioritising wellbeing not ideology. Br J Gen Pract (2013) 0.89
Psychological impact of chronic hepatitis C: comparison with other stressful life events and chronic diseases. World J Gastroenterol (2006) 0.89
Selective hyper-responsiveness of the interferon system in major depressive disorders and depression induced by interferon therapy. PLoS One (2012) 0.88
Effects of comprehensive intervention on health-related quality of life in patients with chronic hepatitis B in China. BMC Health Serv Res (2013) 0.88
Six Minute Walk Test to assess functional capacity in chronic liver disease patients. World J Gastroenterol (2007) 0.87
Assessment of the PHQ-9 as a screening tool for depression in patients with chronic hepatitis C. Dig Dis Sci (2007) 0.87
Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. World J Gastroenterol (2015) 0.87
Changing trends in viral hepatitis-associated hospitalizations in the American Indian/Alaska Native population, 1995-2007. Public Health Rep (2011) 0.87
Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute? J Consult Clin Psychol (2012) 0.87
Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C. Aliment Pharmacol Ther (2010) 0.86
Cancer history and other personal factors affect quality of life in patients with hepatitis C. Health Qual Life Outcomes (2005) 0.84
Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study. BMC Gastroenterol (2012) 0.84
The effect of hepatitis C virus infection on health-related quality of life in prisoners. J Urban Health (2006) 0.84
The Symptom Experience of HIV/HCV-Coinfected Adults. J Assoc Nurses AIDS Care (2008) 0.82
Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: Advances in 2015. World J Gastroenterol (2015) 0.82
Multicountry burden of chronic hepatitis C viral infection among those aware of their diagnosis: a patient survey. PLoS One (2014) 0.82
Characteristics of upper abdominal pain in those with chronic liver disease. Dig Dis Sci (2003) 0.81
Altered quality of life in the early stages of chronic hepatitis C is due to the virus itself. Clin Res Hepatol Gastroenterol (2013) 0.81
Hepatitis C virus infection and health-related quality of life. World J Gastroenterol (2012) 0.81
Health-related quality of life in Greek chronic hepatitis C patients during pegylated interferon and ribavirin treatment. Hippokratia (2010) 0.81
Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia. J Med Virol (2012) 0.80
Fatigue in Patients with Chronic Hepatitis B Living in North America: Results from the Hepatitis B Research Network (HBRN). Dig Dis Sci (2016) 0.80
Frequency of poor quality of life and predictors of health related quality of life in cirrhosis at a tertiary care hospital Pakistan. BMC Res Notes (2012) 0.80
The burden of untreated hepatitis C virus infection: a US patients' perspective. Dig Dis Sci (2012) 0.79
Effects of liver disease on the well-being of persons living with HIV. J Assoc Nurses AIDS Care (2008) 0.79
Optimizing the dose and duration of therapy for chronic hepatitis C. Gut Liver (2009) 0.78
Cost-effectiveness analysis of adding low dose ribavirin to peginterferon alfa-2a for treatment of chronic hepatitis C infected thalassemia major patients in iran. Hepat Mon (2013) 0.78
The cognitive profile of depressed patients with cirrhosis. Prim Care Companion CNS Disord (2011) 0.78
Validation of the MOS-HIV as a measure of health-related quality of life in persons living with HIV and liver disease. AIDS Care (2010) 0.77
Socio-demographic and clinical features of Irish iatrogenic hepatitis C patients: a cross-sectional survey. BMC Public Health (2009) 0.77
Hepatitis C virus infection as a traumatic experience. PLoS One (2014) 0.77
Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection. Clinicoecon Outcomes Res (2010) 0.77
Role of Sleep Disturbance in Chronic Hepatitis C Infection. Curr Hepat Rep (2010) 0.77
Chronic hepatitis C virus infection in children and adolescents: Epidemiology, natural history, and assessment of the safety and efficacy of combination therapy. Adolesc Health Med Ther (2010) 0.77
Impairment of health-related quality of life in patients with chronic hepatitis C is associated with insulin resistance. J Gastroenterol (2013) 0.77
Impact of Hepatitis C Virus Infection on Cognitive Function in Patients With Covert Hepatic Encephalopathy. Hepat Mon (2015) 0.76
Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study. Medicine (Baltimore) (2016) 0.75
Comparison of the prevalence of psychiatric co-morbidities in hepatitis C patients and hepatitis B patients in Saudi Arabia. Saudi J Gastroenterol (2013) 0.75
Health-related quality of life in patients with chronic hepatitis B during antiviral treatment and off-treatment. Patient Prefer Adherence (2017) 0.75
Hepatitis C and poor quality of life: is it the virus or the patient? Saudi J Gastroenterol (2008) 0.75
The Association of Chronic Hepatitis C with Respiratory Microbiota Disturbance on the Basis of Decreased Haemophilus Spp. Colonization. Med Sci Monit (2016) 0.75
Mortality, Hospitalization, and Quality of Life among Patients with Hepatitis C Infection on Hemodialysis. Clin J Am Soc Nephrol (2016) 0.75
Hepatitis B-Related Concerns and Anxieties Among People With Chronic Hepatitis B in Australia. Hepat Mon (2016) 0.75
Mode of transmission, rather than the hepatitis C virus, as a major determinant of poor interpersonal relationships in patients with chronic hepatitis C. Can J Gastroenterol (2007) 0.75
Hepatitis C virus infection, and neurological and psychiatric disorders - A review. J Adv Res (2016) 0.75
Symptom Status Predicts Patient Outcomes in Persons with HIV and Comorbid Liver Disease. AIDS Res Treat (2012) 0.75
Evaluation of the health-related quality of life using the 36-item short form health survey in patients with chronic hepatitis C receiving pegylated interferon/ribavirin/telaprevir triple treatment. Exp Ther Med (2016) 0.75
In the eye of the beholder: assessment of health-related quality of life. Hepatology (1998) 0.75
Clinical utility of pharmacogenomics in the management of hepatitis C. Pharmgenomics Pers Med (2014) 0.75
Brain Microstructural Correlates of Cognitive Dysfunction in Clinically and Biochemically Normal Hepatitis C Virus Infection. J Clin Exp Hepatol (2017) 0.75
Close correlation between the ankle-brachial index and symptoms of depression in hemodialysis patients. Int Urol Nephrol (2017) 0.75
Increase in primary liver cancer in the UK, 1979-94. Lancet (1997) 6.15
Vaccine-induced escape mutant of hepatitis B virus. Lancet (1990) 5.31
Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet (1989) 5.16
Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med (2001) 4.10
Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A (1996) 4.02
Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut (2002) 4.01
Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med (1995) 3.54
Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut (2001) 3.45
Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. Clin Exp Immunol (1978) 3.06
Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet (2000) 2.58
The induction of tolerance to a soluble protein antigen by oral administration. Immunology (1974) 2.50
Is primary biliary cirrhosis an immune complex disease? Lancet (1977) 2.15
Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology (1989) 2.15
Role of the liver in controlling the immunogenicity of commensal bacteria in the gut. Lancet (1973) 2.15
The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat (2011) 2.00
Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient. Gastroenterology (1994) 2.00
Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut (2005) 1.99
Immune complexes in acute and chronic liver disease. Clin Exp Immunol (1978) 1.93
Evidence for a cerebral effect of the hepatitis C virus. Lancet (2001) 1.90
Incidence and clinical significance of e antigen and antibody in acute and chronic liver disease. Lancet (1975) 1.90
Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun (2003) 1.88
Antenatal screening for hepatitis B is medically and economically effective in the prevention of vertical transmission: three years experience in a London hospital. Q J Med (1989) 1.88
Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology (1999) 1.86
The detection of HBV-DNA in serum by molecular hybridisation: a more sensitive method for the detection of complete HBV particles. J Med Virol (1982) 1.81
Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies. J Thromb Haemost (2008) 1.72
Heterozygote advantage for HLA class-II type in hepatitis B virus infection. Nat Genet (1997) 1.71
Short incubation non-A, non-B hepatitis transmitted by factor VIII concentrates in patients with congenital coagulation disorders. Gut (1981) 1.67
Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA. Proc Natl Acad Sci U S A (1991) 1.64
Effects of cyclosporin A on suppressor and inducer T lymphocytes in primary biliary cirrhosis. Lancet (1980) 1.61
Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess (2006) 1.50
Is mitochondrial antibody diagnostic of primary biliary cirrhosis? Gut (1981) 1.50
Non-A, non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin. Lancet (1984) 1.49
Loss of the common "A" determinant of hepatitis B surface antigen by a vaccine-induced escape mutant. J Clin Invest (1992) 1.48
Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology (1997) 1.47
Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum. Hepatology (1985) 1.45
Detection of serum HBV-DNA by molecular hybridisation. Correlation with HBeAg/anti-HBe status, racial origin, liver histology and hepatocellular carcinoma. J Hepatol (1985) 1.43
Peripheral blood lymphocyte populations in chronic liver disease. Clin Exp Immunol (1976) 1.43
Interferon plus amantadine versus interferon alone in the treatment of naïve patients with chronic hepatitis C: a UK multicentre study. J Hepatol (2001) 1.42
Pseudomembranous colitis following clarithromycin therapy. Eur J Gastroenterol Hepatol (1995) 1.40
Significance of delta agent infection in chronic hepatitis B virus infection: a study in British carriers. Gut (1983) 1.40
Recent advances in the molecular biology of hepatitis B virus: mutant virus and the host response. Gut (1993) 1.39
Adenine arabinoside therapy in HBsAg-positive chronic liver disease: a controlled study. Gastroenterology (1981) 1.38
SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J Pharmacol Exp Ther (2000) 1.37
Primary biliary cirrhosis is a dry gland syndrome with features of chronic graft-versus-host disease. Lancet (1980) 1.36
Hepatitis B virus and HLA antigen display in the liver during chronic hepatitis B virus infection. Hepatology (1982) 1.36
Double-stranded DNA-binding capacity of serum in acute and chronic liver disease. Clin Exp Immunol (1976) 1.35
Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. Hepatology (1998) 1.33
Cytotoxic T-cell responses to the nucleocapsid proteins of HBV in chronic hepatitis. Evidence that antibody modulation may cause protracted infection. J Hepatol (1987) 1.33
Protection against hepatitis B virus infection by immunization with hepatitis B core antigen. Gastroenterology (1985) 1.32
HLA class I antigens on the hepatocyte membrane during recovery from acute hepatitis B virus infection and during interferon therapy in chronic hepatitis B virus infection. Hepatology (1986) 1.31
Genetic variation in hepatitis B virus. Gastroenterology (1992) 1.29
Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis. Hepatology (1991) 1.29
HLA-B8, immunoglobulins, and antibody responses in alcohol-related liver disease. J Clin Pathol (1980) 1.28
Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology (1996) 1.27
A rapid one-step radiometric assay for hepatitis B surface antigen utilizing monoclonal antibodies. J Immunol Methods (1982) 1.26
Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut (2005) 1.26
An analysis of the composition of the inflammatory infiltrate in autoimmune and hepatitis B virus-induced chronic liver disease. Hepatology (1983) 1.25
Management of chronic hepatitis C: clinical audit of biopsy based management algorithm. BMJ (1997) 1.24
The immune response in hepatic cirrhosis: animal and human studies. Proc R Soc Med (1977) 1.23
Nitric oxide production by monocytes in alcoholic liver disease. J Hepatol (1992) 1.23
Seroprevalence of hepatitis C virus nucleocapsid antibodies in patients with cryptogenic chronic liver disease. Hepatology (1992) 1.22
Reduction of immune complexes and immunoglobulins induced by D-penicillamine in primary biliary cirrhosis. N Engl J Med (1979) 1.22
Sequence variation in the large envelope glycoprotein (E2/NS1) of hepatitis C virus during chronic infection. J Infect Dis (1993) 1.22
Inducer and suppressor T-cells in hepatitis B virus-induced liver disease. Hepatology (1982) 1.20
The mechanism of replication of hepatitis B virus: evidence of asymmetric replication of the two DNA strands. J Med Virol (1984) 1.18
Staurosporine-induced apoptosis in cardiomyocytes: A potential role of caspase-3. J Mol Cell Cardiol (1998) 1.17
Intracellular localization of the hepatitis B virus HBx protein. J Gen Virol (2001) 1.16
Is the relationship between angiogenesis and metastasis in breast cancer real? Surg Oncol (1992) 1.16
Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group. (Hepatitis C European Network for Co-operative Research. Eur J Gastroenterol Hepatol (2000) 1.16
HBsAg-positive chronic liver disease: inhibition of DNA polymerase activity by vidarabine. Br Med J (1978) 1.15
High risk of non-A non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin. Br J Haematol (1985) 1.15
Antiviral therapy in hepatitis B infection. Br Med Bull (1985) 1.15
Oral infections with Candida albicans. Scott Med J (1973) 1.15
Prevalence of chronic viral hepatitis in people of south Asian ethnicity living in England: the prevalence cannot necessarily be predicted from the prevalence in the country of origin. J Viral Hepat (2009) 1.14
A unique insertion in the S gene of surface antigen--negative hepatitis B virus Chinese carriers. Hepatology (1995) 1.14
Effect of variation in the common "a" determinant on the antigenicity of hepatitis B surface antigen. J Med Virol (2000) 1.13
Lymphocyte populations in liver biopsy specimens from patients with chronic liver disease. Gut (1977) 1.13
T cell subsets in patients with acute and chronic HBV infection, primary biliary cirrhosis and alcohol induced liver disease. Int J Immunopharmacol (1981) 1.13
Acute type A, B, and non-A, non-B hepatitis in a hospital population in London: clinical and epidemiological features. Gut (1983) 1.13
Cerebral dysfunction in chronic hepatitis C infection. J Viral Hepat (2003) 1.13
Evidence for a deficiency of interferon production in patients with chronic hepatitis B virus infection acquired in adult life. Hepatology (1986) 1.12
Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response. Gastroenterology (1999) 1.12
Biopsy pathology of acquired immune deficiency syndrome (AIDS). J Clin Pathol (1987) 1.12
In-vitro synthesis of anti-acetylcholine-receptor antibody by thymic lymphocytes in myasthenia gravis. Lancet (1978) 1.12
Haemorrhagic pancreatitis--a cause of death in severe potassium permanganate poisoning. Postgrad Med J (1990) 1.11
Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers. Lancet (1987) 1.09
Association of low-density lipoprotein receptor polymorphisms and outcome of hepatitis C infection. Genes Immun (2002) 1.09
Cerebral microglial activation in patients with hepatitis C: in vivo evidence of neuroinflammation. J Viral Hepat (2011) 1.09
Ablative therapy for liver tumours. Gut (2002) 1.08
Immune response to phi X 174 in man. 5. Primary and secondary antibody production in primary biliary cirrhosis. Gut (1976) 1.08
A homeostatic mechanism for the removal of antigen from the portal circulation. Immunology (1974) 1.05
Fast and slow twitch muscles in man. J Neurol Sci (1969) 1.05
Food antibodies in oral disease: a study of serum antibodies to food proteins in aphthous ulceration and other oral diseases. J Clin Pathol (1973) 1.04
Diminished responsiveness of homosexual men to antiviral therapy for HBsAg-positive chronic liver disease. J Hepatol (1985) 1.04